Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 101 | 33% |
| 2020 | 1 | 48 | 36% |
| 2021 | 1 | 105 | 39% |
| 2022 | 1 | 83 | 41% |
| 2023 | 2 | 122 | 43% |
| 2024 | 3 | 157 | 45% |
| 2025 forecast | – | 170 143–200 | 46% |
| 2026 forecast | – | 186 146–234 | 46% |
| 2027 forecast | – | 203 151–269 | 47% |
| 2028 forecast | – | 222 157–307 | 47% |
| 2029 forecast | – | 242 165–348 | 47% |
| 2030 forecast | – | 265 173–393 | 48% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Jersey; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2024, 69% surgery center, 31% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 3 | 212+10%/yr | +10%/yr | 0.1 | 16% | 590 in 2030+19%/yr |
| New York | 0 | 175+8.8%/yr | +8.8%/yr | 0.1 | 0% | 450 in 2030+17%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 62 | 2,530−1.6%/yr | −1.6%/yr | 2.30.9× | 4% | 2,680 in 2030+1%/yr |
| Lumbar fusion | 40 | 1,764+6.8%/yr | +6.8%/yr | 1.60.8× | 11% | 2,120 in 2030+3.1%/yr |
| Cervical fusion & disc arthroplasty | 15 | 957+0.5%/yr | +0.5%/yr | 0.90.8× | 0% | 1,050 in 2030+1.5%/yr |
| Kyphoplasty & vertebroplasty | 6 | 624−5.3%/yr | −5.3%/yr | 0.60.7× | 59% | 630 in 2030+0.1%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with Pennsylvania
Globus Medical leads with 56% of company spending on these surgeons in 2025, +45 pts on 2024.
In 2025, 5 companies reported engagement with New Jersey’s surgeons worth $29K in consulting, speaking, meals and travel tied to these products, about $9,515 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.